Exploratory Investigator-Initiated Clinical Trial Using an AI System to Predict Recurrence of Atrial Fibrillation and Assess Completion of Catheter Ablation

未提供0 个研究点目标入组 20 人开始时间: 待定

适应症

试验速览

暂无简介。

•Patients with a history of at least one prior catheter ablation procedure for atrial fibrillation and who are scheduled to undergo catheter ablation for recurrent atrial fibrillation and/or atrial tachycardia.
•Patients for whom the CARTO 3 System is planned to be used as the three-dimensional mapping system.
•Patients aged 18 years or older at the time of obtaining informed consent.
•Patients who, after receiving sufficient explanation regarding participation in this clinical trial and fully understanding the study, provide written informed consent personally.

•Patients with adult congenital heart disease (ACHD).
•Patients who have undergone cardiac surgery involving a right atriotomy.
•Women who are pregnant or suspected of being pregnant.
•Patients who participated in another clinical trial or clinical study within 30 days before obtaining informed consent and received an investigational drug or were treated with an investigational device.
•Patients who are otherwise judged by the principal investigator or sub-investigator to be inappropriate for participation in this clinical trial.

发起方

未提供